OncoCyte's lung cancer liquid biopsy test shows 90% sensitivity

OncoCyte Corp. (NYSE-A:OCX) said Tuesday its DetermaVu liquid biopsy test detected lung cancer with sensitivity of 90% and specificity of 75% in

Read the full 221 word article

User Sign In